Both type 1 and 2 diabetes are caused by inadequate insulin secretion, and in both diseases this can be ascribed in large part to loss of pancreatic ?-cells that produce insulin. Both diseases can be cured by replacement of pancreatic ?-cells by pancreas transplantation but this requires life-long immunosuppression and there are far fewer organ donors than people with diabetes. An alternative approach to restoring pancreatic ?-cells is to foster regeneration of ?-cells in the patient. Recent studies in mice have provided important insights into how ?-cells are formed and their number increased and maintained after birth. Complementary studies in humans are few because of the difficulty in obtaining appropriate material and the difficulty of undertaking lineage tracing studies in humans.

Public Health Relevance

Both type 1 and 2 diabetes are caused by inadequate insulin secretion; and in both diseases this can be ascribed in large part to loss of pancreatic ?-cells that produce insulin. Both diseases can be cured by replacement of pancreatic ?-cells by pancreas transplantation but this requires life-long immunosuppression and there are far fewer organ donors than people with diabetes. An alternative approach is to foster regeneration of ?-cells in the patient him/herself; and the basis of this grant is to explore an approach to that end

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
2R01DK077967-06A1
Application #
8627827
Study Section
Special Emphasis Panel (ZRG1-EMNR-T (02))
Program Officer
Sato, Sheryl M
Project Start
2007-04-01
Project End
2017-06-30
Budget Start
2014-09-11
Budget End
2015-06-30
Support Year
6
Fiscal Year
2014
Total Cost
$334,950
Indirect Cost
$117,450
Name
University of California Los Angeles
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Butler, Peter C (2016) Glucagon-like Peptide 1 Drugs as Second-line Therapy for Type 2 Diabetes. JAMA Intern Med 176:1-3
Md Moin, Abu Saleh; Butler, Peter C; Butler, Alexandra E (2016) Increased Proliferation of the Pancreatic Duct Gland Compartment in Type 1 Diabetes. J Clin Endocrinol Metab :jc20163001
Butler, Alexandra E; Matveyenko, Aleksey V; Kirakossian, David et al. (2016) Recovery of high-quality RNA from laser capture microdissected human and rodent pancreas. J Histotechnol 39:59-65
Md Moin, Abu Saleh; Dhawan, Sangeeta; Shieh, Christine et al. (2016) Increased Hormone-Negative Endocrine Cells in the Pancreas in Type 1 Diabetes. J Clin Endocrinol Metab 101:3487-96
Md Moin, Abu Saleh; Dhawan, Sangeeta; Cory, Megan et al. (2016) Increased Frequency of Hormone Negative and Polyhormonal Endocrine Cells in Lean Individuals With Type 2 Diabetes. J Clin Endocrinol Metab 101:3628-3636
Butler, Alexandra E; Dhawan, Sangeeta; Hoang, Jonathan et al. (2016) β-Cell Deficit in Obese Type 2 Diabetes, a Minor Role of β-Cell Dedifferentiation and Degranulation. J Clin Endocrinol Metab 101:523-32
Gurlo, Tatyana; Butler, Peter C; Butler, Alexandra E (2016) Evaluation of immunohistochemical staining for glucagon in human pancreatic tissue. J Histotechnol 39:8-16
Saisho, Yoshifumi; Butler, Alexandra E; Manesso, Erica et al. (2013) Response to Comment on: Saisho et al. β-cell mass and turnover in humans: effects of obesity and aging. Diabetes Care 2013;36:111-117. Diabetes Care 36:e112
Costes, Safia; Langen, Ralf; Gurlo, Tatyana et al. (2013) β-Cell failure in type 2 diabetes: a case of asking too much of too few? Diabetes 62:327-35
Butler, Peter C; Elashoff, Michael; Elashoff, Robert et al. (2013) A critical analysis of the clinical use of incretin-based therapies: Are the GLP-1 therapies safe? Diabetes Care 36:2118-25

Showing the most recent 10 out of 27 publications